ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

GDR Genedrive Plc

2.40
0.00 (0.00%)
Last Updated: 00:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Genedrive Plc LSE:GDR London Ordinary Share GB00B1VKB244 ORD 1.5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 2.40 2.30 2.50 2.40 2.40 2.40 14,156 00:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Coml Physical, Biologcl Resh 55k -5.15M -0.0095 -2.53 13.04M
Genedrive Plc is listed in the Coml Physical, Biologcl Resh sector of the London Stock Exchange with ticker GDR. The last closing price for Genedrive was 2.40p. Over the last year, Genedrive shares have traded in a share price range of 1.425p to 11.85p.

Genedrive currently has 543,141,481 shares in issue. The market capitalisation of Genedrive is £13.04 million. Genedrive has a price to earnings ratio (PE ratio) of -2.53.

Genedrive Share Discussion Threads

Showing 33326 to 33343 of 33475 messages
Chat Pages: 1339  1338  1337  1336  1335  1334  1333  1332  1331  1330  1329  1328  Older
DateSubjectAuthorDiscuss
12/11/2024
09:34
Quiet you.
premium beeks
12/11/2024
09:07
Lanio that is!
premium beeks
12/11/2024
09:07
Stfu, yfc.TaB
premium beeks
12/11/2024
09:05
Don't forget...

And what the people on the ground said.
The enthusiasm from the doctors was effervescent!





Research posted 31 July, 2024
Manchester leads implementation of lifesaving genetic bedside stroke test

Home News Research Manchester leads implementation of lifesaving genetic bedside stroke test

An innovative bedside genetic test being implemented in Manchester could dramatically improve outcomes for thousands of people in the UK affected by stroke each year.

Developed by researchers from Manchester University NHS Foundation Trust (MFT) and The University of Manchester, in collaboration with Manchester based company genedrive, the test can tell healthcare professionals in approximately one hour if stroke patients will be more likely to benefit from clopidogrel, the current first-line treatment to prevent recurrence.

Approximately 100,000 people in the UK each year will have a stroke – a serious life-threatening condition that happens when the blood supply to part of the brain is cut off by a blood clot.

Clopidogrel prevents platelets (a type of blood cell) from sticking together and forming a dangerous blood clot. However, around 29 per cent of all patients in the UK (and up to 60 per cent in different ethnic groups) have a change in the CYP2C19 gene which reduces clopidogrel’s effectiveness.

Individuals carrying changes in the CYP2C19 gene are also twice as likely to have further strokes when treated with clopidogrel. If these genetic changes can be detected before treatment, then doctors can use an alternative, more effective medicine.

Professor Bill Newman, Consultant in Genomic Medicine at MFT and Professor of Translational Genomic Medicine at The University of Manchester who led the project said: “Strokes affect more than 6,000 people in Greater Manchester each year and those affected are at increased risk of further severe strokes in the following hours, days and weeks.

“This is clearly a particularly worrying time for patients and their families; therefore, it is vital we use new approaches to ensure that patients get onto the right treatment as quickly as possible.”

Professor Newman, who is also Rare Conditions Co-Theme Lead at the National Institute for Health and Care Research (NIHR) Manchester Biomedical Research Centre (BRC), added: “This could reduce time spent in hospital, prevent further strokes, save lives, and avoid future hospital admissions.

hazl
12/11/2024
09:04
What a terrible chart!
Speaks volumes.
What a dog!
Thank goodness for Batiatus for bringing some reality to counter the outrageous ramping.
Be careful who you listen to on here...

ianio5691
12/11/2024
08:57
Professor Bill Newman, Professor of Translational Genomic Medicine at the University of Manchester and Lead
of the NHSE Network of Excellence in Pharmacogenetics and Medicines Optimisation at Manchester University
NHS Foundation Trust, said: “We are delighted to work with genedrive to implement this new clinical test to ensure
that patients following a stroke or a mini-stroke get onto the best treatment as soon as possible to prevent a further
stroke.”
Dr. Natasha James and Dr. Kirsty Ward, Clinical leads for the Greater Manchester CSC, said: “We are delighted to
work with colleagues at Manchester Centre for Genomic Medicine and genedrive to bring the benefit of this novel
technology to Stroke patients in Greater Manchester. The technology will help us to formulate a personalised
optimal treatment plan for Stroke patients, that we hope will prevent future strokes and save lives.

hazl
12/11/2024
08:44
Surely that 230000 trade ought to be in the buy column at 2.24p?
hazl
12/11/2024
08:42
There's a possibility we might even be blue!
hazl
12/11/2024
08:41
Ah that's much more like it!
Bid/offer both higher than yesterday!


IMO

hazl
12/11/2024
08:36
Sub 2 doon
blakesmith
12/11/2024
08:33
Where's batiatus now ? Thanks for the cheap shares Muppet
bones698
12/11/2024
08:23
And watch it turn now .
bones698
12/11/2024
08:04
Somebody has been able to buy in for slightly cheaper than I bought in yesterday, for example.
But not a big difference, I would suggest.

hazl
12/11/2024
08:02
Again the UT Trade last night makes us look as if we are down this morning.
Such a shame!

A technical thing.

hazl
12/11/2024
07:53
This is Genedrive.
Good luck with your investment.

hazl
12/11/2024
07:50
POLX Polarean Imaging will break out above 2p soon. Mcap only $20mil. I see it as a steal for the FDA approved Xenon MRI. No company debt, masssive growth potential in the worlds biggest health market the United States where it's already in 21 clinical settings, best in class next generation MRI. Revenues rising up 3000% to $3mil for 2024 and doubling again next to $6mil. 1.55p and gap at over 3p. ATH 100p. Cash runway to minimum of Q1 2026, looks set to be extended given revenues ahead of expectations.

Putting this UK recovery play potential on radars.

1. September 18th 2024: Interventional radiology vendor Merit Medical to acquire device portfolio for $210M.

APPROX 13P SHARE PRICE EQUIVALENT FOR POLX


2. September 25th 2024: Private equity firm acquiring diagnostic imaging provider for $658M

APPROX 48P SHARE PRICE EQUIVALENT FOR POLX


3. October 14th 2024: Hologic to Acquire Gynesonics The women’s health company will be purchased for approximately $350 million.

APPROX 22P SHARE PRICE EQUIVALENT FOR POLX

4. Bracco current major TR1 Holder of Polarean splashed out $450MILLION for a diagnostic buyout

POLX easy buyout target imv. DYOR, not advice.

m_night10
12/11/2024
07:33
Let's hope for another good day.
You only have to open any of the links in the header to see the strides they 've made in order to get to the point of being a completely productive entity.

IMO

hazl
12/11/2024
06:36
Short reduced to its lowest level in years ,don't listen to batiatus he has sour grapes because he missed the rise to 5p . Very close to the time to start buying here just wait for it to turn and it will move quickly
bones698
Chat Pages: 1339  1338  1337  1336  1335  1334  1333  1332  1331  1330  1329  1328  Older

Your Recent History

Delayed Upgrade Clock